On June 5, 2025, Amicus Therapeutics, Inc. held its Annual Meeting where stockholders elected new directors, approved the 2025 Equity Incentive Plan, ratified Ernst & Young as the accounting firm for 2025, and endorsed executive compensation. Key votes included 256 million for Michael A. Kelly and 253 million for the equity plan.